Nanocis (Rhenium Sulfide)

The exact mechanism of Rhenium sulfide is not publicly disclosed; preliminary research suggests it may interact with metal‑binding proteins and influence cellular redox processes, but detailed pharmacology remains undefined.

The dosage of Nanocis is determined by the prescribing healthcare professional based on the specific investigational protocol or clinical judgment; no standard dosing regimen is established.

Safety of Rhenium sulfide in pregnancy or lactation has not been established; it is generally advised to avoid use unless the potential benefit justifies the potential risk and after consulting a physician.

To place an order, submit an enquiry on the Nanocis product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and required import documentation.

Because Rhenium sulfide has no approved therapeutic class, there is no direct marketed comparator; any comparison would be based on investigational data rather than established efficacy or safety profiles.

Nanocis should be stored at ambient temperature, below 25 °C, in its original packaging, protected from moisture, light and extreme temperatures to maintain stability.

Nanocis can be administered orally or by subcutaneous injection as directed by a qualified healthcare provider; the route and method depend on the specific clinical protocol.

Serious risks are not well defined due to limited clinical data; however, potential concerns include hypersensitivity reactions and unknown organ toxicity, so patients should be monitored closely.

Individuals with known hypersensitivity to Rhenium sulfide, or those for whom the safety profile is uncertain such as pregnant or nursing women, should avoid using Nanocis unless advised otherwise by a physician.